Gilead Sciences, Inc. vs JetBlue Airways Corporation — how do they compare? Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B), while JetBlue Airways Corporation trades at $5.81 (market cap $2.19B). The key difference: Gilead Sciences, Inc. is far larger — about 76.9× JetBlue Airways Corporation's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while JetBlue Airways Corporation pays none. Which is the better fit depends on your goals.
| GILD | JBLU | |
|---|---|---|
Market Cap | $168.35B | $2.19B |
Sector | Health | Industrials |
52-Week High | $155.80 | $6.46 |
52-Week Low | $110.56 | $4.03 |
Enterprise Value | $191.42B | $9.56B |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →